Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01236040 · ClinicalTrials.gov registry record · Phase 1
Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 521
- Enrollment target
NCT01236040 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 521 participants.
The verdict
NCT01236040, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 521 participants
- Enrollment target
Study Summary
This study will assess safety and immunogenicity of GSK Biologicals' H5N1 flu candidate vaccines GSK2590066A and GSK2340273A in healthy adults 18 - 49 years old.
Interventions
- OTHER Placebo
- BIOLOGICAL GSK Biologicals' investigational vaccine GSK2590066A
- BIOLOGICAL GSK Biologicals' investigational vaccine GSK2592984A
- BIOLOGICAL GSK Biologicals' investigational vaccine GSK2340274A
- BIOLOGICAL GSK Biologicals' investigational vaccine GSK2340273A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 521 participants |
| Start Date | 2010-11-29 |
| Est. Completion | 2012-08-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01236040
The ClinicalTrials.gov registry entry for NCT01236040 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 521 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01236040 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01236040 about?
NCT01236040 is a clinical study titled "Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old". This study will assess safety and immunogenicity of GSK Biologicals' H5N1 flu candidate vaccines GSK2590066A and GSK2340273A in healthy adults 18 - 49 years old.
What is the current status of trial NCT01236040?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 521 participants. The study started on 2010-11-29. Estimated completion is 2012-08-20.
What interventions are being tested in trial NCT01236040?
The interventions under investigation include: Placebo (OTHER), GSK Biologicals' investigational vaccine GSK2590066A (BIOLOGICAL), GSK Biologicals' investigational vaccine GSK2592984A (BIOLOGICAL), GSK Biologicals' investigational vaccine GSK2340274A (BIOLOGICAL), GSK Biologicals' investigational vaccine GSK2340273A (BIOLOGICAL).
Who is sponsoring clinical trial NCT01236040?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.